top of page

  Peptide Receptor

Radionuclide

Therapy(Pro-Drug)

​Neuroendocrine tumor

SSTR2

 PRRT, PDC, Pro-drug

​solid cancer

FAP-α

CBT-004

CNP

Achondrogenesis

NPR-B

CBT-005

Project Code

Target

​Indicant

MOA & Molecule Type

Phase 3

Phase 2

Phase 1

Preclinical

Peptide Receptor

Radionuclide Therapy

​Renal cancer

CAIX

CBT-001

Late

Discovery

​Pipeline

Early

Discovery

Target: SSTR2

Indicant: Neuroendocrine tumor

MOA & Molecule Type: Peptide Receptor Radionuclide Therapy

Development stage: R&D

Summary: SSTR2 (Somatostatin Receptor 2) is a membrane protein present in the cell membrane that recognizes Somatostatin (peptide hormone) as a signal and regulates the secretion of hormones. SSTR2 is a target for neuroendocrine tumor treatments, and a representative treatment is Lutathera, a PRRT-based neuroendocrine tumor treatment. We designed a treatment with a Pro-Drug structure and secured a peptide that can bind to FAP-α with high expression around cancer cells. After binding to FAP-α, the peptide was isolated from the treatment and was developed to act only on cancer cells expressing SSTR2. Our company substance can lower toxicity to normal cells and increase specificity to cancer cells compared to Lutathera.

CBT-002

Kidney Cancer

Neuroendocrine Tumor

Solid Cancer

Achondroplasia

Project Code

Target

Indicant

MOA & Molecule Type

Phase 3

Phase 2

Phase 1

Preclinical

Peptide Receptor

Radionuclide Therapy

CAIX

CBT-001

Late

Discovery

  Peptide Receptor

Radionuclide

Therapy(Pro-Drug)

SSTR2

 PRRT, PDC, Pro-drug

FAP-α

CBT-004

CNP

NPR-B

CBT-005

​Pipeline

Early

Discovery

bottom of page